Synapticure Physician - Jaime Hatcher-Martin

Jaime Hatcher-Martin

Movement Disorders Neurologist

4.9

114\ total reviews

Synapticure’s Movement Disorders team is led by Dr. Jaime Hatcher-Martin, a Movement Disorder Specialist who has cared for people with neurodegenerative diseases such as Parkinson’s and Huntington’s Disease for over a decade.

Book an intake (708) 630-1534

Jaime Hatcher-Martin

MD, FAAN

Movement Disorders Neurologist

Request Appointment

Credentials

Residency

Emory University School of Medicine (Neurology)

Fellowship

Emory University School of Medicine (Movement Disorders)

Education

Medical school - Emory University School of Medicine (MD/PhD)

Undergraduate - University of South Florida (BS Biology, minor Gerontology)

Affiliations

2023-current: Huntington Study Group (HSG) Education Committee
2023-current: Huntington Study Group (HSG) Credentialing Committee
2021-current: American Academy of Neurology Medical Economics and Practice (MEP) Telehealth Subcommittee
2019-current: Huntington Study Group (HSG) Family Day Planning Committee
2017-current: International Parkinson’s Disease and Movement Disorders Society Telemedicine Work Group

About the Expert

Biography

Synapticure’s Parkinson’s care team is led by neurologist Dr. Jaime Hatcher-Martin. For over a decade, Dr. Martin has been caring for people with neurodegenerative diseases, specializing in movement disorders like Parkinson’s. With this insight, she recognized the unique burdens on her Parkinson’s patients. Coupled with the fact that many people living with Parkinson’s have no access to specialists, she became a leading advocate to partner telemedicine with expert neurological care.

Prior to joining Synapticure, Dr. Martin practiced at Emory University where she started her own telemedicine clinic for patients with movement disorders in Georgia in 2016, and later at SOC Telemed (now Access Telecare). She is a Fellow of the American Academy of Neurology, served as co-Chair for their Telemedicine Workgroup, where she co-authored their practice guidelines. She also serves on the Telemedicine Study Group for the International Parkinson and Movement Disorder Society and serves on several committees for the Huntington Study Group. Dr. Martin continues to be involved in research related to understanding the toxic exposures that cause or contribute to the meteoric rise in the incidence of Parkinson's Disease.

Publications

Hatcher-Martin JM, McKay J, Sommerfeld B, Howell J, Goldstein F, Factor SA. “Cerebrospinal fluid biomarkers in Parkinson's disease with freezing of gait: an exploratory analysis.” 2021. NPJ Parkinsons Dis. 29(7): 105.

Hatcher-Martin JM and Factor SA. 2016. Freezing of Gait: A Rare Delayed Complication of Whole Brain Radiation. Parkinsonism Relat Disord. 29:129-130.

Factor SA, Hatcher-Martin JM, Morse AS, Nocera JR, Revuelta FJ. 2016. Freezing of gait that disappears: Should there be rest before Rehab? Parkinsonism Relat Disord. 28:169-170.

Hatcher-Martin JM, Shaikh AG, Factor SA. 2015. Chapter 22: Stereotypies in Parkinson’s Disease and Movement Disorders. Jankovic J and Tolosa E (eds). Wolters Kluwer. pp 233-39.

Hatcher-Martin JM, Gearing M, Steenland K, Levey AI, Miller GW, Pennell KD. 2012. Association between polychlorinated biphenyls and Parkinson's disease neuropathology. Neurotoxicology. 33 (5): 1298-1304.

Hatcher JM, Miller GW, Jones DP, Pennell KD. 2008. Chapter 16: Neurotoxicity of manufactured nanoparticles, in Nanoscience and Nanotechnology: Environmental and Health Impact. Grassian, VH (ed). John Wiley & Sons; 405-428.

Hatcher JM, Pennell KD, Miller GW. 2008. Parkinson’s diseases and pesticides: a toxicological perspective. Trends Pharmacol Sci. 29 (6): 322-329.

Hatcher JM, Richardson JR, Guillot TS, McCormack AL, Di Monte DA, Jones DP, Gearing M, Levey AI, Pennell KD, Miller GW. 2007. Elevated levels of the pesticide dieldrin are associated with Parkinson’s disease. Experimental Neurology. 204 (2): 619-630.

Hatcher JM, Delea KC, Richardson JR, Pennell KD, Miller GW. 2008. Disruption of dopamine transport by DDT and its metabolites. Neurotoxicology. 29 (4): 682-690.

Hatcher-Martin JM, Anderson EA, Busis NA, Bove RM, Cohen BH, Fritz JV, Jones EC, Shook SJ, Wolf RA. AAN Telehealth Position Statement. 2021. Neurology. 98(7): 334-339.

Cubo E, Hassan A, Bloem BR, Mari Z… Hatcher-Martin JM… on behalf of the International Parkinson and Movement Disorder Society (MDS) Telemedicine Work Group. 2020. Implementation of Telemedicine for Urgent and Ongoing Healthcare for Patients with Parkinson’s Disease During the COVID-19 Pandemic: New Expectations for the Future. J Parkinsons Dis. 10(3):911-913.

Hatcher-Martin JM, Adams JL, Anderson ER, Bove R, Burrus TM, Chehrenama M, Dolan O'Brien M, Eliashiv DS, Erten-Lyons D, Giesser BS, Moo LR, Narayanaswami P, Rossi MA, Soni M, Tariq N, Tsao JW, Vargas BB, Vota SA, Wessels SR, Planalp H, Govindarajan R. 2020. Telemedicine in neurology: Telemedicine Work Group of the American Academy of Neurology Update. Neurology. 94(1):30-38.

Ben-Pazi H, Browne P, Chan P, Cubo E, Guttman M, Hassan A, Hatcher-Martin JM, Mari Z, Moukheiber E, Okubadejo NU, Shalash A, and the International Parkinson and Movement Disorder Society Telemedicine Task Force. 2018. The Promise of Telemedicine for Movement Disorders: An Interdisciplinary Approach. Invited article for Movement Disorders. Curr Neurol Neurosci Rep. 18(5):26.

Hu WT, Howell JC, Ozturk T, Gangishetti U, Kollhoff AL, Hatcher-Martin JM, Anderson AM, Tyor WR. 2019. Front Immunol. 10:480.

Hatcher-Martin JM, Armstrong KA, Scorr LM, Factor SA. 2016. Propranolol therapy for Tardive Dyskinesia: A retrospective examination. Parkinsonism Relat Disord. 32:124-126.

Arendash GW. King DL. Gordon MN. Morgan D. Hatcher JM. Hope CE. Diamond DM. 2001. Progressive, age-related behavioral impairments in transgenic mice carrying both mutant amyloid precursor protein and presenilin-1 transgenes. Brain Research. 891(1-2):42-53.

Arendash GW. Gordon MN. Diamond DM. Austin LA. Hatcher JM. Jantzen P. DiCarlo G. Wilcock D. Morgan D. 2001. Behavioral assessment of Alzheimer's transgenic mice following long-term A-beta vaccination: task specificity and correlations between A-beta deposition and spatial memory. DNA & Cell Biology. 20(11):737-44.

Gordon MN. King DL. Diamond DM. Jantzen PT. Boyett KV. Hope CE. Hatcher JM, DiCarlo G. Gottschall WP. Morgan D. Arendash GW. 2001. Correlation between cognitive deficits and A beta deposits in transgenic APP+PS1 mice. Neurobiology of Aging. 22(3):377-85.

Morgan D. Diamond DM. Gottschall PE. Ugen KE. Dickey C. Hardy J. Duff K. Jantzen P. DiCarlo G. Wilcock D. Connor K. Hatcher J. Hope C. Gordon M. Arendash GW. 2000. A-beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature. 408(6815):982-5.

Affiliations

2023-current: Huntington Study Group (HSG) Education Committee
2023-current: Huntington Study Group (HSG) Credentialing Committee
2021-current: American Academy of Neurology Medical Economics and Practice (MEP) Telehealth Subcommittee
2019-current: Huntington Study Group (HSG) Family Day Planning Committee
2017-current: International Parkinson’s Disease and Movement Disorders Society Telemedicine Work Group
2020-2021: Children Neurology Foundation Telehealth Initiative
2020-2021: American Academy of Neurology Innovation in Practice Work Group
2020-2021: American Academy of Neurology Teleneurology Education Curriculum for Residents Workgroup
2019-2021: Cerner Neurology Physician Advisor Council
2019-2021: American Academy of Neurology Practice Management and Technology Subcommittee
2020: American Academy of Neurology Telemedicine Reimbursement Work Group
2020: American Academy of Neurology Emergency Telemedicine Work Group
2017-2020: American Academy of Neurology Innovation Hub Working Group
2015-2019: American Academy of Neurology Telemedicine Working Group (Co-Chair)

States Licensed In

Alabama
Alaska
California
Florida
Georgia
Illinois
Indiana
New Jersey
New York
Ohio
Pennsylvania
South Carolina
Texas

Reviews

4.9 Overall Experience

... and many more positive feedback.